EXEL vs UNH

Exelixis continues to demonstrate robust financial performance, driven by its flagship oncology drug, Cabometyx, which showed an 8.1% YoY increase in net product revenues. The company's Q1 2026 results exceeded EPS consensus and delivered strong YoY net income growth of 31.9%. A significant catalyst is the FDA's acceptance of the NDA for zanzalintinib (XL092) in metastatic colorectal cancer, with ...

UnitedHealth Group (UNH) remains a robust, high-quality mega-cap in the mature and highly regulated healthcare sector. Q1 2026 adjusted EPS of $7.23, a recent dividend increase to $2.32, and some analyst upgrades (e.g., Truist to $440, Goldman Sachs Conviction Buy) reflect solid operational performance and financial strength. However, these are characteristics of a stable compounder, not a company...